Key result
A proactive, protocol-driven, inclisiran-based strategy demonstrated superior efficacy in rapid LDL-C goal achievement and reduction while mitigating muscle-related adverse events.
Why the study?
Does a proactive, protocol-driven, inclisiran-based strategy improve LDL-C goal achievement and reduction in high-risk patients?
Does a proactive, protocol-driven, inclisiran-based strategy improve LDL-C goal achievement and reduction in high-risk patients?
Answers are grounded in this paper and cite their sources.
A proactive inclisiran-based strategy offers a model to overcome therapeutic inertia and improve LDL-C goal attainment in high-risk patients.
Bridging the LDL-C Treatment Gap: A Proactive Strategy from the VICTORION-Difference Trial. The graphical abstract summarizes the failure to achieve guideline-recommended LDL-C targets in high-risk patients globally. Key drivers of this treatment gap-including low goal attainment rates, therapeutic inertia, statin-associated symptoms, and demographic disparities. The VICTORION-Difference trial (right panel) provides a model for overcoming these barriers through a proactive, protocol-driven, inclisiran-based strategy, which demonstrated superior efficacy in rapid goal achievement and LDL-C reduction while mitigating muscle-related adverse events. Critical research priorities are needed to translate this evidence into equitable, cost-effective clinical practice and usher in an era of universal lipid target attainment.
No takes yet. Share an insight, caveat, or question.
Miteva et al. (2025) conducted a review in High-risk patients failing to achieve guideline-recommended LDL-C targets. Proactive, protocol-driven, inclisiran-based strategy was evaluated on Rapid goal achievement and LDL-C reduction. A proactive, protocol-driven, inclisiran-based strategy demonstrated superior efficacy in rapid LDL-C goal achievement and reduction while mitigating muscle-related adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: